Dainippon Sumitomo Pharma America selects SAS® Solutions OnDemand: Drug Development to manage clinical trial data

CARY, NC - SAS announced today that Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. pharmaceutical company, has selected SAS Solutions OnDemand: Drug Development as a technology platform for clinical development. With SAS OnDemand, DSPA will have a globally accessible, fully regulatory compliant repository for all of its clinical data.

The SAS OnDemand service has allowed DSPA to move quickly, with limited internal resources, in creating its centralized SAS development environment. By letting SAS handle all system provisioning and deployment activities, DSPA resources are free to focus on other mission critical business activities.


SAS Solutions OnDemand: Drug Development is a cost-effective alternative to an enterprise SAS Drug Development implementation, with all embedded enterprise-level content management and analytical capabilities. SAS, through its OnDemand solution, directly supports all hardware and software installation, system administration, validation and maintenance, freeing DSPA from these burdensome responsibilities.

About SAS
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions delivered within an integrated framework, SAS helps customers at more than 45,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world The Power to Know® .